A genomic "roadmap" to "better" drugs.
Utilization of pharmacogenomic information has the potential to significantly improve treatment outcome and markedly reduce the rate of attrition of drugs in clinical development. A major gap that limits our ability to utilize pharmacogenomic information in drug discovery, drug development or clinical practice is that we often do not know the genetic variants responsible for inter-individual differences in drug metabolism or drug response. We examine emerging genomic methods that can fill this gap; these methods can be used to generate new information about drug metabolism or mechanism of action, or to identify predictors of drug response. Although they have not yet had their full impact, a wider application of these emerging genomic technologies has the potential to significantly improve the safety of drugs, the quality of patient care and the efficiency of clinical drug development.
Liao
Guochun
G
Department of Genetics & Genomics, Roche Palo Alto, Palo Alto, California 94304-1397, USA.
Zhang
Xun
X
Clark
David J
DJ
Peltz
Gary
G
D001711:Biotransformation / Q000235:genetics; D019295:Computational Biology; D015195:Drug Design; D016903:Drug Monitoring; D064420:Drug-Related Side Effects and Adverse Reactions; D005820:Genetic Testing; D014644:Genetic Variation; D023281:Genomics; D005838:Genotype; D006801:Humans; D018579:Patient Selection; D004364:Pharmaceutical Preparations / Q000378:metabolism*; D010597:Pharmacogenetics / Q000379:methods*; D010641:Phenotype
D004364:Pharmaceutical Preparations